Aldeyra Therapeutics Inc. buy stratec
Start price
27.01.18
/
50%
€6.86
Target price
04.11.21
€11.73
Performance (%)
15.24%
End price
05.11.21
€7.90
Summary
This prediction ended on 05.11.21 with a price of €7.90. The BUY prediction by stratec finished with a performance of 15.24%. stratec has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Aldeyra Therapeutics Inc. | 6.217% | 6.217% | -65.946% | - |
iShares Core DAX® | 2.149% | 5.415% | 21.385% | 22.595% |
iShares Nasdaq 100 | 0.838% | 1.926% | 44.386% | 55.330% |
iShares Nikkei 225® | 1.143% | 2.887% | 27.641% | 9.481% |
iShares S&P 500 | 1.265% | 3.698% | 33.327% | 49.646% |
Comments by stratec for this prediction
In the thread Aldeyra Therapeutics Inc. diskutieren
Aldeyra multiple trials are set to read out in the second half of the year
Convincing data has been generated to date, and multiple trials are set to read out in the second half of the year, which will likely lead to a run-up.
Key points to the original bullish thesis included the following:
- The valuation of the company paled in comparison to the sheer size of the opportunity being targeted in the Dry Eye Disease market ($1.8 billion in prescription sales in 2016). The lengths that Allergan (NYSE:AGN) went to try to protect IP for its blockbuster eye treatment Restasis was proof enough of how valuable the DED market is.
- Topical ocular candidate ADX-102 generated encouraging data in a mid-stage study in patients with dry eye disease, with significant improvements recorded across a variety of measures (high statistical significance). Improvements in signs and symptoms of the disease were clear within the first week of therapy and a dose response was observed, with activity increasing throughout the time patients were being treated.
- A potential point of differentiation as compared to other approved dry eye treatments was that ADX-102 reduced levels of pro-inflammatory aldehyde mediator malondialdehyde in patients' tears.
- Lastly, there was more to this story than dry eye disease, as a pivotal study of ADX-102 in allergic conjunctivitis was in the works following feedback from regulatory agencies. The drug could address an adequate response to antihistamines, which affects around one-third of allergic conjunctivitis patients (worldwide prevalence of 20% to 40% of population). Also, results from its phase 3 program in noninfectious anterior uveitis were expected in the second half of 2018 along with preliminary results from a pivotal study in Sjögren-Larsson Syndrome (no FDA approved therapies for the latter).
In the thread Trading Aldeyra Therapeutics Inc.
Die von stratec gewählte maximale Laufzeit wurde überschritten